A Biotech Stock Doubles. XBI Moves About 0.7%.

A drug result lands, one biotechnology company moves hard, and the search traffic goes looking for a biotech ETF. The reasonable assumption is that the fund captures the move. Whether it does depends almost entirely on a design decision most fund pages mention once and never explain.

Three funds carry a healthcare or biotech label and are built differently enough that the same news produces three different outcomes.

Three Funds, One Sector Label, Three Different Machines

Here is what ETF BFF records for each, drawn from the same data that renders the factsheets:

The beta column is the tell. All four are labelled healthcare in one form or another, and they range from 0.70 to 1.10. That spread is not a rounding difference. It is the weighting scheme and the sector definition doing their work.

Equal Weight Is Why a Single Result Barely Registers in XBI

XBI spreads its money close to evenly across its holdings rather than in proportion to company size. With roughly 150 holdings, each one is about 1 divided by 150 of the fund, which is 0.67%.

Now run the case everyone is actually asking about. One holding doubles. Nothing else moves. The contribution to the fund is its weight multiplied by its gain: 0.0067 multiplied by 100% gives 0.67 percentage points.

Reproduce it with one line: weight = 1 / 150 = 0.006667, then 0.006667 × 1.00 = 0.006667, or 0.67%. Real funds use modified equal weight and rebalance on a schedule, so live weights drift from exactly 1/n between rebalances. The order of magnitude holds.

Cap Weight Makes the Same Event Unpredictable

IBB weights by market capitalisation, so the answer to the same question depends entirely on which company moved. If a name is 0.3% of the fund and it doubles, the fund gains about 0.3 points. If a name is 8% of the fund and it doubles, the fund gains about 8 points.

That is a 25-fold difference in outcome from one structural fact, and it means a headline about biotechnology tells you very little about what IBB did that day. You have to know whether the company in the headline was large or small inside the index. In XBI you do not, because the answer is always roughly the same.

XLV Is Mostly Not a Biotech Fund

XLV tracks the S&P Health Care Select Sector index and holds about 63 companies. Large pharmaceutical manufacturers, health insurers, medical device makers and hospital operators sit in there alongside biotechnology. Those businesses have revenue, earnings and in many cases dividends, which is why the fund's recorded beta is 0.70 and its dividend yield is 1.4%.

XBI's recorded dividend yield is 0.0%. That single contrast describes the difference better than any label does. A fund of development-stage biotechnology companies has almost no earnings to distribute, because those companies are spending on research rather than returning cash. Buying XLV after a biotech headline gets you insurers and device makers, most of which had nothing to do with the news.

VHT covers the same sector more broadly at about 420 holdings and 0.10%, which pulls in smaller healthcare companies XLV's 63-name list leaves out.

The Fee Gap Is Real and It Is Not the Main Event

XLV at 0.09% against IBB at 0.44% is a difference of 0.35 percentage points a year, which on $10,000 is $35 annually before any compounding. That is worth knowing and it is not the reason these funds diverge. A beta spread from 0.70 to 1.10 will move a position by more in a single volatile week than the fee gap does across a year.

The order that matters is structure first, then cost. Working out whether you want the whole sector or only biotechnology, and whether you want the outcome to depend on company size, settles more than the expense ratio does. For how expense ratios compound once that is settled, our guide to expense ratios works through the arithmetic, and sector ETFs covers the concentration question these funds raise.

Questions People Ask

What is the difference between XBI and IBB?

Both hold United States biotechnology companies, but they weight them differently. XBI, the SPDR S&P Biotech ETF, uses a modified equal-weight method across roughly 150 holdings at a 0.35% expense ratio, so a very small company counts for close to the same share of the fund as a very large one. IBB, the iShares Biotechnology ETF, weights its roughly 230 holdings by market capitalisation at 0.44%, so the largest companies dominate the result. That single design choice is why the two funds behave differently even when they own many of the same names.

Why does one biotech stock doubling barely move XBI?

Because equal weighting caps how much any one holding can matter. With roughly 150 holdings at approximately equal weight, each position is about 1 divided by 150, or 0.67% of the fund. If one of those holdings doubles and nothing else changes, it contributes about 0.67 percentage points to the fund's return. The arithmetic is 0.0067 multiplied by 100%, which equals 0.67%. The same design that limits any single winner also limits any single failed trial, which is the trade being made.

Is a healthcare ETF the same as a biotech ETF?

No. A healthcare ETF such as XLV or VHT holds the whole sector, which includes large pharmaceutical companies, health insurers, medical device makers and hospital operators alongside biotechnology. Biotechnology is one slice of that, not the whole thing. XLV holds about 63 companies at a 0.09% expense ratio and VHT holds about 420 at 0.10%. A dedicated biotech fund such as XBI or IBB removes the insurers, the device makers and the hospital operators, which is why its recorded beta sits higher.

Why is XBI more volatile than IBB if equal weighting limits single names?

These two effects work in opposite directions and both are real. Equal weighting limits what any individual holding can do to the fund. It also raises the fund's overall exposure to small biotechnology companies, because a company worth a few hundred million gets close to the same weight as one worth many billions. Small biotechs tend to move more, so the fund made of them moves more. ETF BFF records XBI at a beta of 1.10 against IBB at 0.90 and XLV at 0.70.

Do biotech ETFs pay a dividend?

Very little, and in XBI's case the recorded dividend yield is 0.0%. Development-stage biotechnology companies generally spend cash on research rather than returning it to shareholders, so a fund made of them has little income to distribute. Broader healthcare funds do pay more because they hold profitable pharmaceutical companies and insurers: ETF BFF records XLV at a 1.4% yield and VHT at 1.2%, against IBB at 0.3%.